Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. (DTIL) on May 31, 2023. The filing serves as a Regulation FD disclosure and an update on the Company's allogeneic chimeric antigen receptor T cell (CAR T) programs. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates and regulatory milestones rather than financial performance.
Material Changes and Clinical Updates
The Company announced significant interim clinical data for its lead candidate, azercabtagene zapreleucel ("azer-cel"), and its first clinical update on PBCAR19B stealth cell.
- Azer-cel (DLBCL): In 61 evaluable subjects with relapsed/refractory non-Hodgkin lymphoma (NHL), the overall response rate (ORR) was 58% with a 41% complete response (CR) rate.
- CAR T Relapsed Cohort: Among 18 subjects who relapsed following autologous CAR T therapy, ORR was 83% and CR was 61%.
- Durability: In 11 CAR T relapsed subjects, 55% had ongoing durable responses for at least 6 months.
- Recent Cohort: In the most recent cohort (n=5) receiving optimized Dose Level 4b, 60% ORR was achieved, with 66% achieving full molecular remission (MRD-).
- Safety: No Grade 3 or greater cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, or graft versus host disease was observed in the most recent cohort.
- PBCAR19B Stealth Cell (NHL/DLBCL): Designed to evade immune rejection via ARCUS gene editing.
- Phase 1 Results: At Dose Level 2 (540 million cells), 71% ORR and 43% CR were observed across 7 evaluable subjects.
- DLBCL Specifics: In DLBCL patients, ORR was 80% and CR was 60% (MRD-).
- Safety: No Grade 3 or greater CRS, ICANS, infection, or graft versus host disease was observed.
- Mechanism: The stealth cell demonstrated proof of concept in delaying host T and NK cell recovery.
Guidance, Outlook, and Risks
Regulatory Path: A clinical meeting with the U.S. Food and Drug Administration (FDA) is scheduled for June 2023 to discuss next steps for azer-cel in the CAR T relapsed setting. The Company plans to seek partnerships for the ongoing development of PBCAR19B in the earlier line DLBCL setting pending further durability data.
Risks and Contingencies: The filing includes extensive forward-looking statements regarding clinical development, regulatory approval, and funding. Key risks include the ability to become profitable, secure sufficient funding, predict operating expenses, and the success of clinical trials. The Company also notes risks related to genome-editing technology competition, manufacturing challenges, patient enrollment, and potential product liability lawsuits.
Investor Verification Checklist
- Verify the details of the scheduled FDA meeting in June 2023 regarding azer-cel.
- Monitor the Company's cash position and funding requirements, as profitability is not yet achieved.
- Review the full press release (Exhibit 99.1) for complete clinical data tables and safety profiles.
- Assess the timeline for partnership announcements regarding PBCAR19B stealth cell.
- Check subsequent filings for updates on the durability of responses in the CAR T relapsed cohort.